Atara Biotherapeutics Inc
ATRA
Company Profile
Business description
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Contact
1280 Rancho Conejo Boulevard
Suite 200
Thousand OaksCA91320
USAT: +1 805 623-4211
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
14
Stocks News & Analysis
stocks
Is this the catalyst US tech giant needs?
Muse models may just be the spark that the rirm needed in AI model development.
stocks
ASX share plunges due to Iran related weakness
Despite headwinds our long-term outlook is unchanged.
stocks
Investors punish this ASX player after acquisition
We think the floundering stock price is not reflective of underlying asset value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,113.50 | 6.50 | 0.07% |
| CAC 40 | 8,175.56 | 84.04 | -1.02% |
| DAX 40 | 23,561.10 | 242.85 | -1.02% |
| Dow JONES (US) | 47,916.57 | 269.23 | -0.56% |
| FTSE 100 | 10,529.41 | 71.12 | -0.67% |
| HKSE | 25,592.47 | 301.07 | -1.16% |
| NASDAQ | 22,902.89 | 80.48 | 0.35% |
| Nikkei 225 | 56,502.77 | 421.34 | -0.74% |
| NZX 50 Index | 13,020.18 | 161.26 | -1.22% |
| S&P 500 | 6,816.89 | 7.77 | -0.11% |
| S&P/ASX 200 | 8,926.00 | 14.20 | 0.16% |
| SSE Composite Index | 3,988.56 | 2.33 | 0.06% |